Selecta Biosciences (SELB) Announces Quarterly Earnings Results

Selecta Biosciences (NASDAQ:SELB) posted its earnings results on Thursday. The company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.06, MarketWatch Earnings reports. The firm had revenue of $0.01 million during the quarter.

Shares of SELB traded down $0.03 during trading hours on Friday, reaching $2.37. 177,013 shares of the company traded hands, compared to its average volume of 259,822. The firm has a market cap of $106.15 million, a P/E ratio of -0.81 and a beta of 1.50. Selecta Biosciences has a fifty-two week low of $1.41 and a fifty-two week high of $16.55.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Fosun International Ltd boosted its stake in shares of Selecta Biosciences by 153.4% during the first quarter. Fosun International Ltd now owns 438,330 shares of the company’s stock valued at $938,000 after acquiring an additional 265,330 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Selecta Biosciences by 88.3% during the first quarter. BlackRock Inc. now owns 1,691,976 shares of the company’s stock valued at $4,010,000 after acquiring an additional 793,399 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Selecta Biosciences by 80.9% during the first quarter. California State Teachers Retirement System now owns 52,997 shares of the company’s stock valued at $126,000 after acquiring an additional 23,698 shares during the last quarter. Wasatch Advisors Inc. boosted its stake in shares of Selecta Biosciences by 2,546.1% during the first quarter. Wasatch Advisors Inc. now owns 2,923,702 shares of the company’s stock valued at $6,929,000 after acquiring an additional 2,813,212 shares during the last quarter. Finally, American International Group Inc. boosted its stake in shares of Selecta Biosciences by 84.1% during the first quarter. American International Group Inc. now owns 21,814 shares of the company’s stock valued at $52,000 after acquiring an additional 9,962 shares during the last quarter. 23.50% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have weighed in on SELB shares. ValuEngine lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Stifel Nicolaus reissued a “buy” rating and issued a $7.00 target price on shares of Selecta Biosciences in a report on Friday, March 15th. Canaccord Genuity lowered their target price on Selecta Biosciences from $25.00 to $13.00 and set a “buy” rating on the stock in a report on Monday, March 18th. Mizuho lowered their target price on Selecta Biosciences to $4.00 and set a “buy” rating on the stock in a report on Monday, February 4th. Finally, Needham & Company LLC lowered their target price on Selecta Biosciences to $12.00 and set a “buy” rating on the stock in a report on Monday, January 28th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $11.61.

ILLEGAL ACTIVITY NOTICE: “Selecta Biosciences (SELB) Announces Quarterly Earnings Results” was first published by WKRB News and is owned by of WKRB News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.wkrb13.com/2019/05/11/selecta-biosciences-selb-announces-quarterly-earnings-results.html.

About Selecta Biosciences

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.

Featured Article: Roth IRA

Earnings History for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.